1. Generics Bulletin

Advent firms up deal for Sanofi in Europe

Advent International and Sanofi have struck a final deal for the private-equity investment group to acquire Sanofi’s European generics business, Zentiva, through a share purchase agreement worth €1.9 billion (US$2.2 billion). The deal comes after the completion of exclusive negotiations that were announced by the two companies in mid-April (Generics bulletin, 20 April 2018, page 1).

Advent International and Sanofi have struck a final deal for the private-equity investment group to acquire Sanofi’s European generics business, Zentiva, through a share purchase agreement worth €1.9 billion (US$2.2 billion). The deal comes after the completion of exclusive negotiations that were announced by the two companies in mid-April (Generics bulletin, 20 April 2018, page 1).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business